Overview

Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease

Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
The study evaluates the safety and the efficacy of the addition of intravenous transplantation of donor bone marrow mesenchymal stem cells in patients with idiopathic interstitial pneumonia or connective tissue disease associated with interstitial lung disease, which have actively progressing disease with rapid loss of pulmonary function on the background of routine treatment.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Federal Research Clinical Center of Federal Medical & Biological Agency, Russia